Advanced search
Publication Cover
Hematology Volume 17, 2012 - Issue 4
Submit an article Journal homepage
410
Views
5
CrossRef citations to date
0
Altmetric
HEMATOLOGICAL MALIGNANCY

Is there a benefit to adding rituximab to CHOP in the overall survival of patients with B-cell non-Hodgkin’s lymphoma in a developing country?

Guillermo J Ruiz-DelgadoCentro de Hematología y Medicina InternaClínica RUIZ, Puebla, Mexico; Laboratorios Clínicos de Puebla, Clínica RUIZ, Mexico; and Universidad Popular Autónoma del Estado de Puebla, Mexico
,
David Gómez-AlmaguerHospital Universitario de Nuevo León, Mexico
,
Luz C Tarín-ArzagaHospital Universitario de Nuevo León, Mexico
,
Olga G Cantú-RodriguezHospital Universitario de Nuevo León, Mexico
,
Carlos Alarcón UrdanetaCentro de Hematología y Medicina InternaClínica RUIZ, Puebla, Mexico; and Benemérita Universidad Autónoma de Puebla, Mexico
,
Uxmal Rodríguez-MoralesUniversidad Popular Autónoma del Estado de Puebla, Mexico
,
Jackeline Calderón-GarciaCentro de Hematología y Medicina InternaClínica RUIZ, Puebla, Mexico; and Facultad de Medicina, Universidad La Salle, Mexico
,
Omar Fernández-VargasCentro de Hematología y Medicina InternaClínica RUIZ, Puebla, Mexico; and Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Mexico
,
Maryel Montes-MontielCentro de Hematología y Medicina InternaClínica RUIZ, Puebla, Mexico
,
Mónica Sánchez-CárdenasHospital Universitario de Nuevo León, Mexico
&
Guillermo J Ruiz-ArgüellesCentro de Hematología y Medicina InternaClínica RUIZ, Puebla, Mexico; Laboratorios Clínicos de Puebla, Clínica RUIZ, Mexico; and Universidad Popular Autónoma del Estado de Puebla, MexicoCorrespondence[email protected]
 show all
Pages 193-197 | Published online: 18 Jul 2013

References

  • Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al.. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–9.
  • Feugier P, van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al.. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117–26.
  • Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al.. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91.
  • Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs. 2010;70:1445–76.
  • van Meerten T, Hagenbeck A. Novel antibodies against follicular non-Hodgkin’s lymphoma. Best Pract Res Clin Haematol. 2011;24:231–56.
  • McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, et al.. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38:1484–93.
  • Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al.. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–6.
  • Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al.. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas: NCI Sponsored International Working Group [erratum appears in J Clin Oncol. 2000;18:2351]. J Clin Oncol. 1999;17:1244–53.
  • Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457–63.
  • Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al.. International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373–80.
  • Solal-Céligny P, Cahu X, Cartron G. Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? Int J Hematol. 2010;92(2):246–54.
  • Kraus-Weissman A, Ruiz-Argüelles GJ, De-León-Vega O, Pérez-Tamayo R. Estudio sobre linfomas. I. Frecuencia relativa de los linfomas en México. Rev Invest Clin Méx. 1980;32:179–82.
  • Ruiz-Argüelles GJ, Kraus-Weisman A, Pérez-Tamayo R, Montfort I. Estudios sobre linfomas II. Sarcoma Inmunoblástico. Patología Méx. 1980;18:143–65.
  • Ruiz-Argüelles GJ, Mercado-Díaz MA, Ponce-de-León S, Pérez-Tamayo R. Studies on lymphomata. III. Lymphomata, granulomata and tuberculosis. Cancer. 1983;52:258–62.
  • Avilés A, Nambo MJ, Neri N, Cleto S, Castañeda C, Huerta-Guzmàn J, et al.. Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14+R) in high-risk diffuse large cell lymphoma. Med Oncol. 2007;24:85–9.
  • Avilés A, Nambo MJ, Castañeda C, Cleto S, Neri N, Murillo E, et al.. Rituximab and escalated chemotherapy in elderly patients with aggressive diffuse large-cell lymphoma: a controlled clinical trial. Cancer Biother Radiopharm. 2007;22:194–9.
  • Ruiz-Argüelles GJ. Algunas consideraciones respecto al tratamiento actual de los linfomas: la brecha se hace más grande. Med Univ. 2008;10:61–2.
  • Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, et al.. Rituximab plus CHOP (R-CHOP) overcomes Bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101:4279–84.
  • Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM, et al.. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 2006;107:4207–13.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.